Boston Scientific has entered into an agreement to acquire Valencia Technologies for an undisclosed amount, further expanding its urology business. The Boston Scientific Valencia acquisition brings an implantable therapy for bladder dysfunction into the company’s product portfolio.
Valencia Technologies provides treatment for bladder disorders, including with its eCoin implantable tibial nerve stimulation (iTNS) device for the treatment of urge urinary incontinence (UUI), which is a common manifestation of overactive bladder. The agreement comes after Boston Scientific’s acquisition of Axonics back in 2024, and is another recent addition to the company’s Urology segment.
The eCoin device was approved by the U.S. Food and Drug Administration in 2022. The coin-shaped implant is inserted under the skin near the ankle in a minimally-invasive procedure. The product is intended for individuals who have demonstrated a positive response to percutaneous tibial nerve stimulation or are intolerant to or have not had an adequate response to more conservative therapies for UUI.
The implanted device provides intermittent, automatic stimulation to the tibial nerve to regulate signaling between the brain and the bladder. In clinical trials, 68% of patients treated with the device experienced at least a 50% reduction in UUI episodes. Valencia had previously raised $35 million in early 2025 for continued development and commercialization efforts for eCoin.
Boston Scientific expects to complete the transaction in the first half of 2026. The company said the Boston Scientific Valencia acquisition is expected to have an immaterial impact on adjusted earnings per share in 2026, with a more dilutive effect on a GAAP basis.
“The addition of the eCoin system to the Boston Scientific portfolio will enable us to expand into implantable tibial nerve stimulation (ITNS), a high-growth adjacency for our Urology business,” said Meghan Scanlon, SVP and president, Urology, Boston Scientific. “ITNS technology complements our existing pelvic health product line, and we look forward to offering a more comprehensive set of treatment options to patients across the care continuum.”